Italia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
26,15-1,36 (-4,94%)
Alla chiusura: 04:00PM EDT
25,00 -1,15 (-4,40%)
Dopo ore: 06:18PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente27,51
Denaro25,00 x 2900
Lettera27,25 x 800
Min-Max giorno25,14 - 27,79
Intervallo di 52 settimane12,71 - 42,16
Media Volume1.470.450
Beta (5 anni mensile)1,94
Rapporto PE (ttm)N/D
EPS (ttm)-2,01
Prossima data utili08 ago 2022 - 12 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A76,57
  • GlobeNewswire

    ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    -- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint

  • GlobeNewswire

    ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

    SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.

  • GlobeNewswire

    ChemoCentryx Announces Changes to its Board of Directors

    -- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an independent director, and Henry A. McKinnell, Jr., Ph.D., is retiring from the Board, effective May 26, 2022. “Dr. David E. Wheadon adds strength and d